AFFILIATIONS
1 Hospital de la Santa Creu i Sant Pau, Institut de Recerca Sant Pau (IR SANT PAU) and José Carreras Leukemia Research Institutes, Universitat Autónoma de Barcelona, Barcelona, Spain
2 EBMT Study unit, Paris, France
3 EBMT Study unit, Paris, France
4 EBMT Study unit, Paris, France
5 University Hospital Eppendorf, Hamburg, Germany
6 IRCCS San Raffaele Hospital Scientific Institute, Milan, Italy
7 University of Muenster, Munster, Germany
8 Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany
9 University of Heidelberg, Heidelberg, Germany
10 University Hospital Regensburg, Regensburg, Germany
11 Gazi University Faculty of Medicine, Ankara, Turkey
12 University Hospital, Basel, Switzerland
13 University of Cologne, cologne, Germany
14 Klinikum Augsburg, Augsburg, Germany
15 Institute of Hematology and Blood Transfusion, Prague, Czech Republic
16 University Hospital of Internal Medicine V (Hematology and Oncology), Medical University of Innsbruck, Innsbruck, Austria
17 University Hospitals Leuven and Department of Public Health and Primary Care, ACCENT VV, KU, Leuven, Belgium
18 Comprehensive Cancer Centre, King's College London, London, United Kingdom
19 Hematology Department, Institut Catala d'Oncologia, Hospital Duran i Reynals, L'Hospitalet De Llobregat, IDIBELL Universitat de Barcelona, Barcelona, Spain
20 Rijeka University Hospital Centre, Rijeka, Croatia
21 Rigshospitalet, Copenhagen, Denmark
22 RM Gorbacheva Research Institute, Pavlov University, Saint Petersburg, Russian Federation
23 Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Oncology and Tumorimmunology, Berlin, Germany
ABSTRACT
Background: Relapse after a second allogeneic hematopoietic stem cell transplantation (HSCT) is generally considered a palliative condition. However, novel therapies may induce remission and prolong survival, thereby enabling consideration of a third HSCT (HSCT3) in fit selected cases. There is currently no contemporary large-scale analysis addressing outcomes following HSCT3 for malignant diseases.
Methods: on behalf of the CWP of EBMT, we retrospectively investigated outcomes of 193 adult patients who underwent HSCT3 between 2000 and 2024. Patients with hematological malignancies, in all disease states and with engraftment prior HSCT3 and relapse between first and second HSCT were included. Patients with non-malignant diseases and who received a CD34+ boost without conditioning were excluded.
Results: The median follow-up was 72.05 (95%CI 59.69-120.76) months. Median age at HSCT3 was 45 (min-max) [IQR] (31.2-55) [40.5-49.5] years. The majority of patients were male (n=108, 56%). Diagnosis at HSCT3 was acute leukemia in 152 (79%), myelodysplastic syndrome in 15 (8%), myeloproliferative neoplasm in 9 (4%), chronic myeloid leukemia in 7 (4%), plasma cell disorder in 6 (3%) and lymphoma in 4 (2%) patients. It was the same diagnosis as the two previous HSCTs in 95% (n=183) of the cases. Disease status at HSCT3 was complete remission (CR) in 61 (32%) and Karnofsky performance score was ≥80% in 140 (81%) patients. Median year of HSCT3 was 2015 (min-max) [IQR] (2001-2024) [2010-2019]. The majority of patients received an unrelated transplant (n=91, 47%) and graft source was peripheral blood stem cell in 87% (n=168). Only in few cases did patients receive HSCT3 from the same donor (n=14, 10%). Chemotherapy regimen was a reduced intensity conditioning in 122 (64%) and TBI was part of the conditioning in 39 (21%) cases. Median time from second to third HSCT was 1.6 (min-max) [IQR] (0.1-14.3) [0.8-2.8] years. Neutrophil engraftment was 85.2% [95%CI 79.1-89.6] at 30 days. The 2-year and 6-year overall survival (OS) were 26.4% [95%CI 20.8-33.6] and 14.2% [95%CI 9.5-21], respectively. Death was transplant-related in 28% and due to relapse in 69% of the cases. Progression free survival (PFS) was 21.2% [95%CI 16-28.3] and 11.5% [95%CI 7.2-18.3] at 24 and 72 months. Relapse incidence was 52.5% [95%CI 44.8-59.6] at 24 months and 58.8% [95%CI 50.8-66] at 72 months. Non-relapse mortality was 26.3% [95%CI 20-32.9] at 24 months and 29.7% [95%CI 22.9-36.8] at 72 months. Grade II-IV acute graft-versus-host disease at 100 days was 31.3% [95%CI 24.2-38.6]. In multivariate analysis adjusted for time from second to third allogeneic HSCT, age, Karnofsky score and disease status at HSCT3, longer time from second to third allogeneic transplant was associated with a significantly better OS (HR 0.88 for a 1-year increment [95%CI 0.79-0.97], p=0.012) and PFS (HR 0.86 [95%CI 0.77-0.96], p=0.007) and with a lower relapse incidence (HR 0.81 [95%CI 0.7-0.95], p=0.007). Not being in CR at HSCT3 was associated with higher risk of relapse (HR 1.87 [95%CI 1.04-3.39], p=0.038). Older age (HR 1.21 [95%CI 1.04-1.42], p=0.015) and not being in CR (HR 1.5 [95%CI 1.01-2.23], p=0.042) were associated with non-engraftment risk.
Conclusion: A third allogeneic transplant is unsurprisingly associated with high non-relapse mortality. Nonetheless, it can result in long-term survival in a subset of patients, mostly limited to late relapses after second HSCT and patients with response to a re-induction therapy
DISCLOSURES
Annalisa Paviglianiti, MD, PhD: No relevant conflicts of interest to declare.